Vertex Pharmaceuticals Inc. (Nasdaq: VRTX) reported upbeat results from a midstage clinical trial of its cystic fibrosis treatment Kalydeco sending the stock price surging $18.59 to $56.00.
Upbeat Results For Vertex Pharmaceuticals
May 07, 2012 at 13:58 PM EDT
